Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India

Tropical Medicine and International Health

Volumn 9, Issue 6, 2004, Pages 702-709

  Babu, B V ^a   Kar, S K ^a  

^a REGIONAL MEDICAL RESEARCH CENTRE ICMR   (India)

Author keywords

Albendazole; Diethylcarbamazine; India; Lymphatic filariasis; Mass drug administration; Orissa

Indexed keywords

ALBENDAZOLE; DIETHYLCARBAMAZINE;

COMPLIANCE; DISEASE CONTROL; DRUG PRESCRIBING; FILARIASIS;

ADULT; ARTICLE; CONTROLLED STUDY; EDUCATION PROGRAM; FEMALE; FILARIASIS; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; INFECTION CONTROL; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT EDUCATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RURAL AREA; URBAN AREA;

ADOLESCENT; ALBENDAZOLE; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DIETHYLCARBAMAZINE; DRUG THERAPY, COMBINATION; ELEPHANTIASIS, FILARIAL; ENDEMIC DISEASES; FEMALE; FILARICIDES; HEALTH PERSONNEL; HUMANS; INDIA; MALE; PATIENT COMPLIANCE; PROGRAM EVALUATION;

ASIA; EURASIA; INDIA; ORISSA; SOUTH ASIA;

NEMATODA;

EID: 3042591837     PISSN: 13602276     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2004.01247.x     Document Type: Article

References (35)

1. Babu BV & Satyanarayana K (2003) Factors responsible for coverage and compliance in mass drug administration during the programme to eliminate lymphatic filariasis in the East Godavari district, South India. Tropical Doctor 33, 79-82.
2. Babu BV, Acharya AS, Mallick G, Jangid PK, Nayak AN & Satyanarayana K (2001) Lymphatic filariasis in Khurda district of Orissa, India: an epidemiological study. Southeast Asian Journal of Tropical Medicine and Public Health 32, 240-243.
3. Babu BV, Hazra RK, Chhotray GP & Satyanarayana K (2004) Knowledge and beliefs about elephantiasis and hydrocele of lymphatic filariasis and some socio-demographic determinants in an endemic community of Eastern India. Public Health 118, 121-127.
4. Biritwum RB, Sylla M, Diarra T et al. (1997) Evaluation of ivermectin distribution in Benin, Cote d'Ivoire, Ghana and Togo: estimation of coverage of treatment and operational aspects of distribution system. Annals of Tropical Medicine and Parasitology 91, 297-305.
5. Bockarie MJ, Tisch DJ, Kastens W et al. (2002) Mass treatment to eliminate filariasis in Papua New Guinea. New England Journal of Medicine 347, 1841-1848.
6. CDC (1993) Recommendations of the international task force for disease eradication. Morbidity and Mortality Weekly Report 42, 1-38.
7. Chhotray GP, Mohapatra M, Acharya AS & Ranjit MR (2001) A clinico-epidemiological perspective of lymphatic filariasis in Satyabadi block of Puri district, Orissa. Indian Journal of Medical Research 114, 65-71.
8. Das PK, Ramaiah KD, Augustine DJ & Kumar A (2001) Towards elimination of lymphatic filariasis in India. Trends in Parasitology 17, 457-460.
9. Dash AP, Mahapatra N, Hazra RK & Acharya AS (1998) Transmission dynamics of filariasis in Khurda district of Orissa, India. Southeast Asian Journal of Tropical Medicine and Public Health 29, 137-140.
10. Esterre P, Plichart C, Sechan Y & Nguyen NL (2001) The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort. Tropical Medicine and International Health 6, 190-195.
11. Hudelson PM (1994) Qualitative Research for Health Programmes. Document No. WHO/MNH/PSF/94.3. World Health Organisation, Geneva.
12. Ismail MM, Jayakody RL, Weil GJ et al. (1998) Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 92, 94-97.
13. Ismail MM, Jayakody RL, Weil GJ et al. (2001) Long-term efficacy of single-dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Transactions of the Royal Society of Tropical Medicine and Hygiene 95, 332-335.
14. Khan ME, Anker M, Patel BC, Barge S, Sadhwani H & Kohle R (1991) The use of focus groups in social and behavioural research: some methodological issues. World Health Statistics Quarterly 44, 145-149.
15. Krishnamoorty K, Ramu K, Srividya A et al. (2000) Cost of annual mass single dose DEC distribution for the large scale control of lymphatic filariasis in Cuddalore district, India. Indian Journal of Medical Research 110, 81-89.
16. Kumar A & Chand SK (1990) Prevalence of Wuchereria bancrofti infection in some coastal villages of Ganjam, Orissa. Journal of Communicable Diseases 22, 209-212.
17. Kumar A, Dash AP & Mansing GD (1994) Prevalence of filariasis in rural Puri. Journal of Communicable Diseases 26, 215-220.
18. McLaughlin SI, Radday J, Michel MC et al. (2003) Frequency, severity and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti 2000. American Journal of Tropical Medicine and Hygiene 68, 568-573.
19. Matubazi D & Duke BOL (1998) Onchocerciasis control in Uganda: how can self sustaining, community based treatment with ivermectin be achieved? Annals of Tropical Medicine and Parasitology 92, 195-203.
20. Michael E, Bundy DAP & Grenfell BT (1996) Reassessing the global prevalence and distribution of lymphatic filariasis. Parasitology 112, 409-428.
21. Molyneux DH & Zagaria N (2002) Lymphatic filariasis elimination: progress in global programme development. Annals of Tropical Medicine and Parasitology 96, S15-S40.
22. Norman RA, Chan MS, Srividya A et al. (2000) EPIFIL: the development of an age-structured model for describing the transmission dynamics and control of lymphatic filariasis. Epidemiology and Infection 124, 529-541.
23. Ottesen EA, Vijayasekaran V, Kumaraswami V et al. (1990) A controlled trail of ivermectin and diethylcarbamazine in lymphatic filariasis. New England Journal of Medicine 322, 1113-1117.
24. Ottesen EA, Duke BOL, Karam M & Behbehani K (1997) Strategies and tools for the control/elimination of lymphatic filariasis. Bulletin of the World Health Organization 75, 491-503.
25. Ottesen EA, Ismail MM & Horton J (1999) The role of albendazole in programme to eliminate lymphatic filariasis. Parasitology Today 15, 382-386.
26. Pelto PJ & Pelto GH (1978) Anthropological Research: the Structure of Enquiry. Cambridge University Press, Cambridge.
27. Plaisier AP, Stolk WA, Van Ooortmarssen GJ & Habbema JDF (2000) Effectiveness of annual ivermectin treatment for Wuchereria bancrofti infection. Parasitology Today 16, 298-302.
28. Ramaiah KD, Das PK, Appavoo NC et al. (2000) A programme to eliminate lymphatic filariasis in Tamil Nadu state, India: compliance with annual single dose mass treatment and some related operational aspects. Tropical Medicine and International Health 5, 842-847.
29. Rath RN, Mohapatra BN & Das B (1989) Bancroftian filariasis in two selected rural communities in Puri district, Orissa - a comparative study of filariometric data. Journal of Communicable Diseases 21, 39-40.
30. Remme JHF, Alley ES & Plaisier AP (1995) Estimation and prediction in tropical disease control: the example of onchocerciasis. In: Epidemic Models: their Structure and Relation to Data (ed. D Mollison) Cambridge University Press, Cambridge, pp. 372-392.
31. Savioli L, Crompton DWT, Ottesen EA, Montresor A & Hayashi S (1997) Intestinal worms beware: development in anti-helminthic chemotherapy usage. Parasitology Today 13, 43-44.
32. Stephenson I & Wiselka M (2000) Drug treatment of tropical parasitic infections: recent achievements and developments. Drugs 60, 985-995.
33. Taylor MJ, Bandi C, Hoerauf AM & Lazdins J (2000) Wolbachia bacteria of filarial nematodes: a target for control? Parasitology Today 16, 179-180.
34. WHO (2000) Preparing and Implementing a National Plan to Eliminate Lymphatic Filariasis in Countries where Onchocerciasis is Not Co-endemic. WHO/CDC/CPE/CEE/2000.15. World Health Organization, Geneva.
35. WHO (2001) Macroeconomics and Health: Investing for Health for Economic Development. World Health Organization, Geneva.